Presentation (CTI)

OBJECTIVES: To assess post-trial real-world (RW) treatment patterns, discontinuation, adherence and healthcare resource use (HCRU) among women with vasomotor symptoms (VMS) using linked RW data from OASIS STAR registry.
METHODS: Twenty-seven OASIS trial participants were linked to Komodo Healthcare Map data to assess outcomes over 6-month post-trial period. The Full Analysis Set (FAS) included 27 patients; 11 with continuous pharmacy enrollment comprised the treatment patterns cohort. Descriptive analyses evaluated treatment use, duration, adherence (medication possession ratio [MPR], proportion of days covered [PDC]), HCRU, and per-patient-per-month (PPPM) costs.
RESULTS: In the FAS, 18/27 patients (66.7%) remained untreated post-trial; 22.2% received hormonal therapy and 25.9% non-hormonal therapy (categories were not mutually exclusive). Hormonal treatments included estradiol/estriol (18.5%) and progestogens (11.1%); non-hormonal therapies included SSRIs/SNRIs (18.5%) and NK3 receptor antagonists (11.1%). Median treatment duration was longer for hormonal versus non-hormonal therapy (5.1 vs 3.0 months). Adherence was higher with hormonal versus non-hormonal therapies (MPR: 1.2 vs 0.7; PDC: 0.7 vs 0.4). No hospitalizations occurred; ER visits were observed only among untreated patients (7.4%). Primary care visits were the most common HCRU. Mean PPPM healthcare provider costs were lower among treated versus untreated patients ($105 vs $183), while pharmacy costs were higher ($116 vs $32).
CONCLUSIONS: Despite trial participation, most patients remained untreated post-trial, indicating persistent gaps in VMS management. Untreated patients showed higher HCRU, suggesting potential economic burden associated with suboptimal care. Use of newer non-hormonal treatments reflects evolving treatment patterns. Findings are descriptive and limited by small sample size.